for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Crinetics Pharmaceuticals Inc

CRNX.OQ

Latest Trade

14.72USD

Change

-0.01(-0.07%)

Volume

22,248

Today's Range

14.51

 - 

15.06

52 Week Range

10.63

 - 

26.65

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Crinetics Pharmaceuticals Plans To Advance Lead Acth Antagonist Into Phase 1 Single-Ascending Dose

Sept 4 (Reuters) - Crinetics Pharmaceuticals Inc <CRNX.O>::CRINETICS PHARMACEUTICALS PROVIDES NEW DATA FROM PALTUSOTINE AND ACTH ANTAGONIST DEVELOPMENT PROGRAMS AT EUROPEAN CONGRESS OF ENDOCRINOLOGY.CRINETICS PHARMA - PLANS TO ADVANCE LEAD ACTH ANTAGONIST INTO PHASE 1 SINGLE-ASCENDING DOSE, MULTIPLE-ASCENDING DOSE STUDIES IN LATE 2020 OR EARLY 2021.CRINETICS PHARMACEUTICALS - IN PHASE 1 STUDY, PALTUSOTINE PROVIDED A FAVORABLE MEAN ORAL BIOAVAILABILITY OF 70%.CRINETICS PHARMA - RESULTS OF PHASE 1 STUDY SUGGEST PALTUSOTINE SHOWS PROPERTIES APPROPRIATE FOR CHRONIC ONCE-DAILY ORAL TREATMENT OF ACROMEGALY PATIENTS.

Crinetics Pharmaceuticals Reports Q2 2020 Financial Results And Provides Corporate Update

Aug 7 (Reuters) - Crinetics Pharmaceuticals Inc <CRNX.O>::CRINETICS PHARMACEUTICALS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALED $205.2 MILLION AS OF JUNE 30.QTRLY LOSS PER SHARE 53 CENTS.Q2 EARNINGS PER SHARE VIEW $-0.57 -- REFINITIV IBES DATA.

Crinetics Pharmaceuticals Reports First Quarter 2020 Financial Results And Provides Corporate Update

May 8 (Reuters) - Crinetics Pharmaceuticals Inc <CRNX.O>::CRINETICS PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.CRINETICS PHARMACEUTICALS INC QTRLY NET LOSS PER SHARE $0.71.CRINETICS PHARMACEUTICALS INC - CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALED $112.8 MILLION AS OF MARCH 31, 2020.

Crinetics Pharmaceuticals Prices Public Offering Of 7.15 Mln Common Stock

April 15 (Reuters) - Crinetics Pharmaceuticals Inc <CRNX.O>::CRINETICS PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 7.15 MILLION COMMON SHARES PRICED AT $14.00PER SHARE.

Crinetics Pharmaceuticals Announces Proposed Public Offering Of Common Stock

April 14 (Reuters) - Crinetics Pharmaceuticals Inc <CRNX.O>::CRINETICS PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.CRINETICS PHARMACEUTICALS INC - INTENDS TO USE NET PROCEEDS FROM PROPOSED OFFERING TO FUND DEVELOPMENT OF PALTUSOTINE.

Crinetics Pharmaceuticals Reports Q4 Loss Per Share Of $0.60

March 9 (Reuters) - Crinetics Pharmaceuticals Inc <CRNX.O>::CRINETICS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.CRINETICS PHARMACEUTICALS INC QUARTERLY LOSS PER SHARE $0.60.CRINETICS PHARMACEUTICALS INC QUARTERLY GRANT REVENUES $321,000 VERSUS $781,000.CRINETICS PHARMACEUTICALS - EXPECTS THAT CASH, CASH EQUIVALENTS AND INVESTMENTS WILL FUND CURRENT OPERATING PLAN INTO SECOND HALF OF 2021.

Crinetics Pharmaceuticals Reports Third Quarter Results

Nov 12 (Reuters) - Crinetics Pharmaceuticals Inc <CRNX.O>::CRINETICS PHARMACEUTICALS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.CRINETICS PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.60.CRINETICS PHARMACEUTICALS INC - UNRESTRICTED CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALED $131.7 MILLION AS OF SEPTEMBER 30, 2019.

Crinetics Pharmaceuticals Files For Mixed Shelf Of Up To $300 Mln

Aug 13 (Reuters) - Crinetics Pharmaceuticals Inc <CRNX.O>::CRINETICS PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $300 MILLION – SEC FILING.

Crinetics Pharmaceuticals Inc Reports Quarterly Loss Per Share Of $0.51

Aug 13 (Reuters) - Crinetics Pharmaceuticals Inc <CRNX.O>::CRINETICS PHARMACEUTICALS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.CRINETICS PHARMACEUTICALS INC- QTRLY LOSS PER SHARE $0.51.CRINETICS PHARMACEUTICALS - UNRESTRICTED CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALED $145.0 MILLION AS OF JUNE 30, 2019.

Crinetics Pharmaceuticals Inc Posts Q4 Loss Per Share of $0.35 - SEC Filing

March 13 (Reuters) - Crinetics Pharmaceuticals Inc <CRNX.O>::CRINETICS PHARMACEUTICALS INC - Q4 LOSS PER SHARE $0.35 - SEC FILING.CRINETICS PHARMACEUTICALS INC - CASH, CASH EQUIVALENTS & SHORT-TERM INVESTMENTS OF $163.9 MILLION AS OF DEC 31, 2018, VERSUS $14.2 MILLION AS OF DECEMBER 31, 2017.CRINETICS PHARMACEUTICALS INC QTRLY GRANT REVENUES $781,000 VERSUS $528,000.CRINETICS PHARMACEUTICALS INC - EXPECTS ITS CASH, CASH EQUIVALENTS AND INVESTMENTS WILL FUND ITS CURRENT OPERATING PLAN AT LEAST THROUGH END OF 2020.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up